CORDIS
EU research results

CORDIS

English EN
Hybrid optical and optoacoustic endoscope for esophageal tracking.

Hybrid optical and optoacoustic endoscope for esophageal tracking.

Objective

More than 450.000 people are diagnosed with esophageal cancer (EC) each-year worldwide and approximately 400.000 die from the disease. Esophageal cancer is the eighth most commonly diagnosed cancer, but it is the sixth leading cause of cancer-related death, with incidence rates steeply rising. Risk factors, including gastroesophageal reflux disease and Barrett’s esophagus, may diagnostically implicate more than 300 million people worldwide. Nevertheless, the disease is detected late due to limitations in current diagnostic procedures leading to adverse prognosis and high treatment costs. ESOTRAC will change the landscape of esophageal diagnosis, over existing methods, based on cross-sectional optoacoustic and optical coherence endoscopy. The dual-modality system delivers a set of early-cancer imaging features necessary for improving early diagnosis, saving lives and leading to 3-5 Billion annual savings for the healthcare system. OCT provides micron scale subsurface morphological information based on photon scattering and optoacoustics provides deeper penetration and complementary pathophysiological features based on photon absorption. ESOTRAC develops novel photonic components (light sources, optical/optoacoustic scopes) and innovates novel medical system designs. Then, it performs pilot studies to investigate the functionality of the new endoscope and deliver a novel imaging-feature portfolio offering improved and earlier diagnosis. A central ESOTRAC ambition is that the new endoscope will become the new EC diagnostic standard by enabling quantitative and label-free three-dimensional endoscopy of early cancer with tremendous potential to impact esophageal care. ESOTRAC leverages European investment and know-how and strengthens the prospects of economic growth by leading the market position in endoscopic imaging.

Coordinator

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Address

Ingolstadter Landstrasse 1
85764 Neuherberg

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 876 710

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 343 265

SONAXIS SA

France

EU Contribution

€ 244 218,75

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 527 500

RAYFOS LTD

United Kingdom

EU Contribution

€ 372 500

ASCENION GmbH

Germany

EU Contribution

€ 198 750

AMPLITUDE SYSTEMES SA

France

EU Contribution

€ 517 500

DANMARKS TEKNISKE UNIVERSITET

Denmark

EU Contribution

€ 371 250

STATICE SAS

France

EU Contribution

€ 548 908,75

Project information

Grant agreement ID: 732720

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2020

Funded under:

H2020-EU.2.1.1.

  • Overall budget:

    € 4 000 602,50

  • EU contribution

    € 4 000 602,50

Coordinated by:

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

Germany